The company was founded in 2016 and is currently working on a new treatment for ARDS using a repurposed drug that is already marketed worldwide for other indications. This new treatment has the potential to significantly reduce the mortality and morbidities associated with ARDS, and also reduce the costs of caring for critically ill patients. Exvastat's drugs help healthcare providers to cure patients of lung edema and improve patient outcomes.